Designing a potent L1 protein-based HPV peptide vaccine: A bioinformatics approach

Yazdani, Zahra; Rafiei, Alireza; Valadan, Reza; Ashrafi, Hossein; Pasandi, MarziehSharifi; Kardan, Mostafa

doi:10.1016/j.compbiolchem.2020.107209

Cited by 31 publications

(28 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 It was used broadly as an adjuvant in vaccine structure designed against viral infections such as influenza 85,87,88 and HPV. 25,89 In addition, we incorporated HP-91 and HBD-3 in the final vaccine construct. The peptide of HP-91 derived from B-box domain amino acids of 89-108 from HMGB1 protein.…”

Section: Discussionmentioning

confidence: 99%

“…Bioinformatic approaches are very helpful to identify the effective epitopes and developing vaccines. Several vaccine candidates for viral diseases have been reported based on this approach that include effective vaccines in Human papilloma viridea (HPV), 25 Ebola, 26 Zika 27 and MERS 28,29 viruses. There are few reports of COVID-19 vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

Self Cite

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2. Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensinconverting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli. Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli .

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intranasal administration of Flagellin stimulates the signaling of TLR5 in lung epithelial cells and pneumonocytes [80]. It was used broadly as adjuvant in vaccine structure designed against viral infections such as influenza [79, 81, 82] and HPV[23, 83]. In addition, we incorporated HP-91 and HBD-3 in the final vaccine construct.…”

Section: Discussionmentioning

confidence: 99%

“…Bioinformatic approaches are very helpful to identify the effective epitopes and developing vaccine. Several vaccines for virus diseases were designed based on these approaches that include effective vaccines on Human papilloma viridea (HPV) [23],Ebola [24], Zika[25]and MERS[26, 27]viruses. There are also few reports of a vaccine candidate for COVID19[28, 29].…”

Section: Introductionmentioning

confidence: 99%

Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis

Yazdani

Rafiei

Yazdani

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective for SARS-CoV-2 infection. Therefore, we implemented immunoinformatics approach to design an efficient multi-epitopes vaccine against SARS-CoV-2.Results: The designed vaccine construct has several immunodominant epitopes from structural proteins of Spike, Nucleocapsid, Membrane and Envelope. These peptides promote cellular and humoral immunity and Interferon gamma responses. In addition, these epitopes have antigenicity ability and no allergenicity probability. To enhance the vaccine immunogenicity, we used three potent adjuvants; Flagellin, a driven peptide from high mobility group box 1 as HP-91 and human beta defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. Tertiary structure of the vaccine protein was predicted and refined by I-Tasser and galaxi refine and validated using Rampage and ERRAT. Results of Ellipro showed 242 residues from vaccine might be conformational B cell epitopes. Docking of vaccine with Toll-Like Receptors 3, 5 and 8 proved an appropriate interaction between the vaccine and receptor proteins. In silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli.Conclusions: The designed multi epitope vaccine is potentially antigenic in nature and has the ability to induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, this vaccine has high quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli.

show abstract

“…Similarly, various immuno-informatics methods were used to develop a probable vaccine coding in the Mtb H37Rv genome for multiple B and T cell epitopes. They could potentially activate both humoral and cellular immunity 32 . Our finding proposed that the selected epitopes from the four Mtb antigens [Rv2608, Rv2684, Rv3804c (Ag85A), and Rv0125 (Mtb32A)] could be used effectively as potential candidates for vaccines and will be applied for future experimental research to eradicate TB.…”

mentioning

confidence: 99%

In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology

Bibi

Ullah

Zhu

et al. 2021

Sci Rep

132

View full text Add to dashboard Cite

Tuberculosis (TB) kills more individuals in the world than any other disease, and a threat made direr by the coverage of drug-resistant strains of Mycobacterium tuberculosis (Mtb). Bacillus Calmette–Guérin (BCG) is the single TB vaccine licensed for use in human beings and effectively protects infants and children against severe military and meningeal TB. We applied advanced computational techniques to develop a universal TB vaccine. In the current study, we select the very conserved, experimentally confirmed Mtb antigens, including Rv2608, Rv2684, Rv3804c (Ag85A), and Rv0125 (Mtb32A) to design a novel multi-epitope subunit vaccine. By using the Immune Epitopes Database (IEDB), we predicted different B-cell and T-cell epitopes. An adjuvant (Griselimycin) was also added to vaccine construct to improve its immunogenicity. Bioinformatics tools were used to predict, refined, and validate the 3D structure and then docked with toll-like-receptor (TLR-3) using different servers. The constructed vaccine was used for further processing based on allergenicity, antigenicity, solubility, different physiochemical properties, and molecular docking scores. The in silico immune simulation results showed significant response for immune cells. For successful expression of the vaccine in E. coli, in-silico cloning and codon optimization were performed. This research also sets out a good signal for the design of a peptide-based tuberculosis vaccine. In conclusion, our findings show that the known multi-epitope vaccine may activate humoral and cellular immune responses and maybe a possible tuberculosis vaccine candidate. Therefore, more experimental validations should be exposed to it.

show abstract

Designing a potent L1 protein-based HPV peptide vaccine: A bioinformatics approach

Cited by 31 publications

References 56 publications

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis

In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology

Contact Info

Product

Resources

About